阿托伐他汀强化治疗对ACS合并糖尿病患者介入术后C一反应蛋白的影响(1)
 |
| 第1页 |
参见附件。
[摘要]目的：研究不同剂量阿托伐他汀对合并糖尿病的ACS患者经皮冠状动脉介入(PCI)治疗术后炎症因子、调脂疗效的影响。方法：对72例合并糖尿病的ACS患者行冠状动脉介入术，随机分为阿托伐他汀20mg组(A组)36例，40mg组(B组)38例，手术当天、术后24小时、术后2周、术后4周空腹采血，测定血清高敏C一反应蛋白(hs.CRP)以及血脂水平。结果：阿托伐他汀40mg组较20mg组PCI术后血清hs—CRP浓度降低更明显。2组术后2周血脂水平较术前略有降低，但无统计学意义，两组术后4周血脂水平较术前降低，阿托伐他汀40mg组较20mg组PCI术后血清低密度脂蛋白(LDL-C)浓度降低更明显。结论：冠脉介入术后患者血清hs-CRP升高；阿托伐他汀能降低冠脉介入术后患者血清hs-CRP，LDL—C水平40mg阿托伐他汀治疗较20mg阿托伐他汀疗效更好。
[关键词]糖尿病；ACS；阿托伐他汀；经皮冠状动脉介入术；c反应蛋白
[Abstract]Objective: study the different doses for Atorvastatin patients with diabetes to merge the ACS percutaneous coronary intervention (PCI) treatment of postoperative inflammatory factor, and lipid curative effect. Method: do intraoperative coronary intervention for 72 cases of patients with diabetes mellitus ACS, randomized intraoperative atorvastatin 20mg group (group A) (36 cases) and 40mg group (group B) 38 cases, surgery and postoperative day 24 hours, after two weeks, postoperative 4 weeks, determine fasting blood serum gao min C-reactive protein (CRP) and hs ......
您现在查看是摘要介绍页，详见PDF附件。